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Abstract
Background: The search for sickle cell disease (SCD) prognosis biomarkers is a challenge. These markers
identification can help to establish further therapy, later severe clinical complications and with patients follow-up.
We attempted to study a possible involvement of levels of high-density lipoprotein cholesterol (HDL-C) in steady-
state children with SCD, once that this lipid marker has been correlated with anti-inflammatory, anti-oxidative, anti-
aggregation, anti-coagulant and pro-fibrinolytic activities, important aspects to be considered in sickle cell disease
pathogenesis.
Methods: We prospectively analyzed biochemical, inflammatory and hematological biomarkers of 152 steady-state
infants with SCD and 132 healthy subjects using immunochemistry, immunoassay and electronic cell counter
respectively. Clinical data were collected from patient medical records.
Results: Of the 152 infants investigated had a significant positive association of high-density lipoprotein cholesterol
with hemoglobin (P < 0.001), hematocrit (P < 0.001) and total cholesterol (P < 0.001) and a negative significant
association with reticulocytes (P = 0.046), leukocytes (P = 0.015), monocytes (P = 0.004) and platelets (P = 0.005),
bilirubins [total bilirubin (P < 0.001), direct bilirubin (P < 0.001) and indirect bilirubin (P < 0.001], iron (P < 0.001),
aminotransferases [aspartate aminotransferase (P = 0.004), alanine aminotransferase (P = 0.035)], lactate
dehydrogenase (P < 0.001), urea (P = 0.030), alpha 1-antitrypsin (P < 0.001), very low-density lipoprotein cholesterol
(P = 0.003), triglycerides (P = 0.005) and hemoglobin S (P = 0.002). Low high-density lipoprotein cholesterol
concentration was associated with the history of cardiac abnormalities (P = 0.025), pneumonia (P = 0.033) and
blood transfusion use (P = 0.025). Lipids and inflammatory markers were associated with the presence of
cholelithiasis.
Conclusions: We hypothesize that some SCD patients can have a specific dyslipidemic subphenotype
characterized by low HDL-C with hypertriglyceridemia and high VLDL-C in association with other biomarkers,
including those related to inflammation. This represents an important step toward a more reliable clinical
prognosis. Additional studies are warranted to test this hypothesis and the probably mechanisms involved in this
complex network of markers and their role in SCD pathogenesis.
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Background
Sickle cell disease (SCD) clinical outcomes vary widely
from mild to severe and the disease has been associated
with multi-organ damage and risk of early mortality
[1,2]. Acute and chronic clinical manifestations of SCD
include vaso-occlusive pain episodes (VOE), impaired
blood flow as a result of intravascular sickling in capil-
laries and small vessels, inflammation processes and
high susceptibility to infection. Researchers have found
a complex network of associations among laboratory
analyses and clinical events predicting a probably risk of
death [1,3,4].
The sickle cell disease vaso-occlusive phenomenon has
been described as a complex event with the participa-
tion of stressed reticulocytes, sickled erythrocytes, leuko-
cytes, platelets and endothelium activation [2,5-8].
Reactive oxygen species (ROS), scavenger molecules and
nitric oxide (NO) play important roles as regulators of
vascular homeostasis in SCD pathogenesis [9].
Several biomarkers have been associated with SCD
clinical prognosis; some, such as fetal hemoglobin (HbF)
concentration, leukocytes count and reticulocyte count
are considered to be classic [2,5]. Recently, serum lactate
dehydrogenase (LDH), a well-known marker of intravas-
cular hemolysis, was described as a biomarker of prog-
nosis in SCD [10]. It has been associated with nitric
oxide resistance, priapism, leg ulceration, pulmonary
hypertension, and death in SCD patients [11].
We conducted a prospective study to investigate high-
density lipoprotein cholesterol (HDL-C) levels, including
also determination of total cholesterol, low-density lipo-
protein cholesterol (LDL-C), very low-density lipopro-
tein cholesterol (VLDL-C) and triglycerides to test the
hypothesis that they can be used as a marker of prog-
nosis among steady-state sickle cell disease children.
This potential biomarker and their association with
others laboratory determination and medical history
were investigated in order to identify sub-phenotypes
associated with the disease.
Subjects and Methods
Subjects and Controls
Of 152 steady-state SCD children from Salvador city,
state of Bahia, in Brazil were prospectively analyzed for
laboratory (biochemical and hematological) markers.
Brazil is the largest country in South America, with one
of the most heterogeneous populations due to several
waves of immigration that have resulted in cultural,
socioeconomic, and ethnic diversity in different geo-
graphic regions. Salvador is the largest city in Bahia, a
Northeastern Brazilian state. Among the local popula-
tion, 86% is of African origin, and Salvador has the
highest incidence of SCD in Brazil [12].
The study was conducted from March 2007 to
November 2008 and included patients from the Funda-
ção de Hematologia e Hemoterapia do estado da Bahia
(HEMOBA), a reference center attending to sickle cell
disease patients who are seen for routine visits at the
outpatient clinic. The study also included 132 healthy
children randomly selected from the Clinical Laboratory
of the Faculdade de Farmácia da Universidade Federal
da Bahia (UFBA); these were matched to cases by age,
gender and African ethnic origin as a control group.
The study was approved by the Fundação de Pesquisa
Oswaldo Cruz human subject research board, and all
officials responsible provided written informed consent,
in accordance with the Declaration of Helsinki of 1975,
as revised in 2000.
Laboratory Methods
Clinical laboratory analyses were performed in the Clini-
cal Analyses Laboratory of the PHAR-UFBA and the
Pathology and Molecular Biology Laboratory of the Cen-
tro de Pesquisas Goncalo Moniz da Fundação de Pes-
quisa Oswaldo Cruz. Biochemical markers analyses were
measured in serum by immunochemistry assay (A25
system, BIOSYSTEMS SA, Barcelona, Spain). Serum fer-
ritin was measured by immunoassay using an Access®
2 Immunoassay system X2 (Beckman Coulter, Fullerton,
CA). C-reactive protein (CRP), alpha 1-antitripsin
(A1AT) and antistreptolysin-O (ASO) were measured by
immunochemistry (Immage® 800 system, Beckman Coul-
ter, Fullerton, CA). Hematological analyses were carried
out using an electronic cell counter, Coulter Count
T-890 (Coulter Corporation, FL, USA). The hemoglobin
(Hb) profile and HbF levels were investigated by high
performance liquid chromatography (HPLC/VARIANT
I; BIO-RAD, CA, USA).
Definition of Clinical Events
Clinical data were collected from patient medical
records. Demographic data were provided by interviews
with patients and parents or guardians. Eligibility criteria
included only SCD patients of pediatric age. All patients
were in the steady-state of the disease when samples
were collected; steady-state was characterized as a per-
iod without any acute events and no blood transfusion
for 120 days prior to blood sampling. Exclusion criteria
included infection or inflammatory episodes and pre-
vious blood transfusion (within four months prior to the
study). To identify possible associations between HDL-C
levels and clinical characteristics in SCD we assessed
medical history from patients’ records, including preva-
lence of stroke, number of hospitalizations, painful
episodes, VOE, infection, pneumonia, priapism, spleno-
megaly, splenic sequestration, leg ulcers, cardiac
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abnormalities, respiratory insufficiency and cholelithiasis.
Pneumonia was defined as an acute infection of the lung
by virus, bacteria or atypical organisms with a clinical
outcome that did not meet the criteria for ACS [8].
Statistical analysis
Baseline characteristics were summarized as means and
proportions of selected variables. Distribution of quanti-
tative variables was determined using the Kolmogorov-
Smirnov test. Mean values of quantitative variables
between groups were compared using the unpaired
t-test for normal data distribution and Mann-Whitney
for non-normal data. Bivariate correlation analyses were
carried out to determine correlations between pairs of
variables using Pearson’s and Spearman’s rank correla-
tion (R). The nonparametric Kruskal-Wallis test was
used to compare means among two or more groups as
measured by interval variables. The level of 40 mg/dl
was considered as a reference range and interactions
between low HDL-C (less than 40 mg/dl) and high
HDL-C (at least 40 mg/dl) and baseline characteristics
were evaluated using independent t-test and Mann-
Whitney tests. The interactions between low HDL-C
(less than 40 mg/dl) and high HDL-C (at least 40 mg/
dl) and specific categorical clinical variables were tested
for significance using a c2 test or Fisher’s exact test, tak-
ing into account the expected frequency in the cell
tables. All tests were considered significant if p values
were less than .05. Data analyses were performed using
Prism 5.01 (Graphpad Software, San Diego, CA), EPIinfo
6.04 (CDC, Atlanta, Georgia) and STATA SE 10 soft-
ware (StataCorp, Texas, USA).
Results
First of all we compared the analyses of markers of
intravascular hemolysis, hemolysis and hepatic involve-
ment, leukocyte and platelet counts, renal involvement,
lipid metabolism, inflammation and Hb profile in
order to establish how much are the difference
between those markers between control and patients
groups (Table 1).
HDL-C association with markers of hemolysis,
inflammation and vascular dysfunction
The high-density lipoprotein cholesterol was positively
correlated with red blood cells (RBC), Hb, hematocrit
and total cholesterol and urea concentrations and nega-
tively correlated with hematimetric indexes of mean cell
volume (MCV), mean cell hemoglobin (MCH) and
mean cell hemoglobin concentration (MCHC); reticulo-
cytes, hemoglobin S (HbS), hemolysis and hepatic mar-
kers, total leukocytes, monocytes and platelets, alanine
aminotransferase (ALT), iron and A1AT. However,
it was not correlated with LDL-C. Steady state
triglycerides were negatively correlated with RBC, Hb,
hematocrit and HDL-C, and positively correlated with
HbS, LDH, AST, total bilirubin, platelet, total protein,
total cholesterol, and VLDL-C (Table 2).
We next determined whether the levels of HDL-C in
SCD group (HDL-C less than 40 mg/dl vs. 40 mg/dl or
more) showed difference among the laboratorial mar-
kers. In the first group, there were 80 HBSS and
23 HBSC patients, and in the second group, there were
23 HBSS and 25 HBSC patients. Sickle cell patients with
low HDL-C presented lower RBC counts as well as Hb
and hematocrit concentrations than patients from the
group with normal HDL-C levels. The low concentra-
tion HDL-C group had higher erythroblast, leukocyte,
platelet, neutrophil, monocyte and reticulocyte counts
and higher iron, AST, total bilirubin, direct bilirubin,
indirect bilirubin, LDH and A1AT concentrations.
There was no difference in LDL-C concentration
between the two HDL-C subgroups, but the VLDL-C
and triglycerides concentrations were higher in the low
HDL-C group (Table 3).
Association of HDL-C with sickle cell disease clinical
history
We assessed possible associations between HDL-C levels
and a series of clinical characteristics in SCD medical
history, including prevalence of stroke, number of hospi-
talizations, painful episodes, VOE, infection, pneumonia,
priapism, splenomegaly, splenic sequestration, leg ulcers,
cardiac abnormalities, respiratory insufficiency and cho-
lelithiasis. To compare these categorical variables with
HDL-C concentration, we divided patients into two
groups. The low HDL-C group (less than 40 mg/dl)
comprised 103 sickle cell disease patients (80 HBSS and
23 HBSC), with an HDL-C range of 16-39 mg/dl and
mean of 28.95 mg/dl. The high HDL-C group (at least
40 mg/dl) comprised 48 SCD patients (23 HBSS and
25 HBSC), with an HDL-C range of 41-85 mg/dl and
mean of 51.2 mg/dl.
The prevalence of pneumonia (OR = 2.42, 95%CI:
1.06-5.53; P = 0.033) and the prevalence of cardiac
abnormalities (OR = 2.88, 95%CI: 1.12-7.59, P = 0.025)
were significantly different between the HDL-C groups.
Forty-one children in the low HDL-C group had cardiac
abnormalities typical of hemolytic anemia on ausculta-
tion. However, among these, 24 had electrocardiograph
arrhythmia, and 3 had tricuspid regurgitant jet velocity
of at least 2.6 m/sec, indicating a possible presence of
pulmonary hypertension. These results were obtained
from previously performed echocardiograms that were
not preformed at the same time of the present study.
The low HDL-C concentration group underwent more
blood transfusions (OR = 2.52, 95%CI: 1.11-5.77,
P = 0.025).
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Table 1 Patient and control group characteristics
Patients Controls
Characteristics N Mean ± SD N Mean ± SD p
Age (Years) 152 9.2 ± 4.0 132 8.7 ± 3.2
Gender
Male 82 53.9* 68 51.5*
Female 70 46.1* 64 48.5*
Hemoglobins
AA – — 132 100.0
SS 103 67.8 – —
SC 48 31.5 – —
SD 01 0.7 – —
Hemoglobin
Fetal (%) 142 7.51 ± 6.20 130 0.47 ± 0.46 <0.001
Hemolysis
RBC (× 106/cu mm) 152 3.24 ± 0.97 131 4.74 ± 0.39 <0.001
Hemoglobin (g/dL) 152 8.93 ± 2.01 131 12.83 ± 1.03 <0.001
Hematocrit (%) 152 27.65 ± 6.20 131 38.47 ± 2.78 <0.001
Mean Cell Volume (fL) 152 87.44 ± 10.85 131 81.37 ± 5.16 <0.001
Mean Cell Hemoglobin (pg) 152 28.29 ± 3.73 131 27.14 ± 1.95 0.007
Reticulocyte Count (%) 140 7.61 ± 4.88 122 0.846 ± 0.256 <0.001
Leukocytes
Leukocyte Count (× 109/L) 152 13.1 ± 5.8 131 7.0 ± 2.2 <0.001
Neutrophil Count (× 109/L) 152 6161.72 ± 3779.49 131 3240.32 ± 1686.15 <0.001
Monocyte Count (× 109/L) 152 817.15 ± 481.83 131 488.67 ± 204.90 <0.001
Platelets
Platelet Count (× 109/L) 152 403.93 ± 158.66 131 308.21 ± 67.35 <0.001
Lipid metabolism
Total Cholesterol (mg/dL) 151 121.12 ± 26.16 124 164.08 ± 34.55 <0.001
HDL Cholesterol (mg/dL) 151 35.65 ± 12.34 123 48.90 ± 13.67 <0.001
LDL Cholesterol (mg/dL) 151 64.95 ±22.19 123 97.41 ± 33.54 <0.001
VLDL Cholesterol (mg/dL) 151 20.44 ± 9.38 123 17.75 ± 10.37 <0.001
Triglycerides (mg/dL) 150 102.07 ± 46.86 123 88.31 ± 51.73 0.002
Hemolysis plus Hepatic
Aspartate aminotransferase (U/L) 152 48.05 ± 24.92 122 30.28 ± 11.13 <0.001
Total bilirubin (mg/dL) 151 2.73 ± 1.76 118 0.49 ± 0.21 <0.001
Direct bilirubin (mg/dL) 151 0.66 ± 0.46 118 0.250 ± 0.082 <0.001
Indirect bilirubin (mg/dL) 151 2.08 ± 1.59 118 0.244 ± 0.182 <0.001
Iron serum (mcg/dL) 126 123.40 ± 119.94 119 71.14 ± 40.31 <0.001
Lactate dehydrogenase(U/L) 151 858.22 ± 503.81 119 406.27 ± 132.03 <0.001
Hepatic
Alanine aminotransferase (U/L) 152 28.25 ± 21.34 121 17.36 ± 7.10 <0.001
Total protein (g/dL) 151 7.33 ± 0.848 119 7.31 ± 0.62 0.695
Albumin (g/dL) 151 4.07 ± 0.675 119 4.24 ± 0.49 0.249
Globulin (g/dL) 151 3.26 ± 0.781 119 3.06 ± 0.63 0.109
Albumin/Globulin ratio 151 1.35 ± .54 112 1.44 ± .42 0.289
Renal
Urea nitrogen (mg/dL) 150 17.73 ± 6.41 120 21.65 ± 5.92 <0.001
Creatinine (mg/dL) 151 0.51 ± 0.50 120 0.523 ± 0.185 0.708
Inflammation
C-reactive protein (mg/L) 148 7.08 ± 11.97 102 2.01 ± 2.29 <0.001
Alpha 1-antitrypsin (mg/dL) 151 152.50 ± 46.18 129 137.48 ± 43.36 0.013
Ferritin (ng/mL) 152 313.32 ± 361.44 117 37.29 ± 28.28 <0.001
Antistreptolysin-O(UI/mL) 148 192.70 ± 285.42 101 132.75 ± 131.19 0.181
* percentage Mann-Whitney test
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High serum levels of LDL-C, VLDL-C and total cho-
lesterol lipoproteins, TRIG, ferritin and A1AT but not
HDL-C were associated with the occurrence of chole-
lithiasis (Figure 1).
Discussion
The present study analyzed levels of HDL-C in steady-
state children with SCD. Children with SCD, even in
steady-state, have differences in several biomarkers as
compared to healthy age-matched children [13]. Those
differences are related to numerous mechanisms asso-
ciated with infection, inflammation and VOE in the dis-
ease [1,2]. Several biomarkers associated with hemolysis,
inflammation, renal metabolism, hepatic metabolism,
and lipid metabolism in children with SCD and healthy
subjects were studied, and the findings of normal con-
centrations of protein and globulin as well as the albu-
min/globulin ratio among the SCD patients suggest an
absence of early severe liver cell damage in the studied
group [13]. Normal levels of creatinine in the patient
group confirm previous observations that an increased
rate of creatinine secretion by dysfunctional renal
tubules may lead to a falsely normal plasma creatinine
and creatinine clearance. A more accurate evaluation of
different aspects of SCD nephropathy, emphasizing pro-
teinuria and hyperfiltration, needs to be developed in
children in order to detect early renal alteration [14-16].
Hypocholesterolemia has been described in SCD
patients with significantly decreased LDL-C and HDL-C
[17-22] and has been also described for our group as a
potential biomarker for SCD clinical severity [23]. A
negative association was found for HDL-C and VLDL-C,
which was directly associated with triglycerides. Trigly-
ceride-rich VLDL-C particles availability may play an
important role in lipid oxidization in SCD patients. It
has been suggested that VLDL-C is an important factor
for atherosclerosis development. VLDL-C particles
assemble by a complex process that includes an apolipo-
protein B (apoB)-containing VLDL precursor and a
VLDL-sized lipid droplet lacking apoB. Both particles
fuse to produce a mature VLDL particle [24]. The
increase of triglycerides probably contributes to an
increase in the hepatic production of VLDL-C, increas-
ing the number of receptors for LDL-C that is exten-
sively metabolized, decreasing its serum levels. However,
the role of cholesterol and triglycerides and the regula-
tion of assembly and production of VLDL-C are poorly
understood.
A negative association was observed between LDH
and HDL-C, showing that HDL-C, as measured by its
Table 2 Laboratory value associations with HDL-C and





r p r p
Hemoglobin
S hemoglobin (%) -0.311 0.002 0.286 0.005
Fetal hemoglobin (%) -0.048 0.644 -0.685 0.685
Hemolysis
RBC (× 106/cu mm) 0.328 <0.001 -0.190 0.019
Hemoglobin (g/dL) 0.292♣ <0.001 -0.202 0.013
Hematocrit (%) 0.309 <0.001 -0.189 0.020
Mean Cell Volume (fL) -0.273♣ 0.006 0.126 0.125
Mean Cell Hemoglobin (pg) -0.284♣ 0.002 0.111 0.175
Reticulocyte Count (%) -0.170♣ 0.046 0.082 0.339
Leukocyte
Leukocyte Count (× 109/L) -0.198♣ 0.015 0.081 0.325
Neutrophil Count (× 109/L) 0.017♣ 0.838 -0.154 0.061
Monocyte Count (× 109/L) -0.234 0.004 0.139 0.089
Platelets
Platelet Count (× 109/L) -0.228♣ 0.005 0.233 0.004
Hemolysis plus Hepatic
Aspartate aminotransferase (U/L) -0.235♣ 0.004 0.207 0.011
Total bilirubin (mg/dL) -0.298♣ <0.001 0.165 0.044
Direct bilirubin (mg/dL) -0.471 <0.001 0.035 0.669
Indirect bilirubin (mg/dL) -0.287 <0.001 0.140 0.088
Iron Serum (mcg/dL) -0.186 0.038 0.159 0.076
Lactate dehydrogenase (U/L) -0.375 <0.001 0.167 0.041
Hepatic
Alanine aminotransferase (U/L) -0.172 0.035 0.075 0.364
Total protein (g/dL) -0.021♣ 0.793 0.274 0.001
Albumin (g/dL) 0.102 0.213 0.142 0.083
Globulin (g/dL) -0.124♣ 0.129 0.133 0.104
Albumin/Globulin ratio 0.033 0.689 -0.033 0.684
Renal
Urea nitrogen (mg/dL) 0.178 0.030 0.020 0.806
Creatinine (mg/dL) 0.118 0.152 0.105 0.201
Lipid metabolism
Total Cholesterol (mg/dL) 0.299♣ <0.001 0.268 0.001
HDL Cholesterol (mg/dL) —— —— -0.228 0.005
LDL Cholesterol (mg/dL) -0.083♣ 0.312 0.068 0.409
VLDL Cholesterol (mg/dL) -0.242 0.003 0.998 <0.001
Triglycerides (mg/dL) -0.228 0.005 —— ——
Inflammation
C-reactive protein (mg/L) 0.048 0.563 -0.031 0.714
Alpha 1 antitrypsin (mg/dL) -0.327♣ <0.001 -0.074 0.378
Ferritin (ng/mL) -0.032 0.699 0.102 0.220
Antistreptolysin O (UI/mL) -0.079 0.339 0.157 0.058
Spearman or Pearson correlation coefficients (r) and p values (p) ♣ r =
Pearson correlation coefficient
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Table 3 Laboratory values for sickle cell disease patients with different steady-state levels of HDL-C
**HDL less than 40 mg/dL ***HDL at least 40 mg/dL
N Mean ± SD N Mean ± SD *p
Hemolysis
RBC (× 106/cu mm L) 103 3.01 ± 0.85 48 3.75 ± 1.0 <0.001
Hemoglobin (g/dL) 103 8.57 ± 2.02 48 9.76 ± 1.75 0.001
Hematocrit (%) 103 26.42 ± 6.17 48 30.43 ± 5.37 <0.001
Mean Cell Volume (fL) 103 89.17 ± 10.34 48 83.52 ± 11.01 0.003
Mean Cell Hemoglobin (pg) 103 28.94 ± 3.52 48 26.82 ±3.79 0.001
Mean Cell Hemoglobin Concentration (%) 103 32.44 ± 0.96 48 32.07 ± 0.86 0.025
Erythroblast (%) 103 1.90 ± 2.31 48 1.02 ± 2.48 0.034
Reticulocyte count (%) 97 8.34 ± 4.55 42 5.90 ± 5.25 0.006
Hemoglobins
S hemoglobin (%) 97 79.22 ± 16.16 44 60.75 ± 18.22 <0.001
Fetal hemoglobin (%) 97 7.55 ± 5.99 44 7.41 ± 6.78 0.899
Leukocyte
Leukocyte Count (× 109/L) 103 14105.83 ± 6085.37 48 10868.75 ± 4416.13 0.001
Neutrophil Count (× 109/L) 103 6723.36 ± 4167.75 48 4971.83 ± 2459.10 0.002
Monocyte Count (× 109/L) 103 910.35 ± 499.84 48 604.69 ± 361.83 0.004
Platelets
Platelet Count (× 109/L) 103 424.90 ± 160.26 48 357.69 ± 148.02 0.015
Hemolysis plus Hepatic
Aspartate aminotransferase (U/L) 103 51.45 ± 26.29 48 40.65 ± 20.32 0.013
Total bilirubin (mg/dL) 103 3.13 ± 1.82 48 1.88 ± 1.25 <0.001
Direct bilirubin (mg/dL) 103 0.79 ± 0.47 48 0.38 ± 0.25 <0.001
Indirect bilirubin (mg/dL) 103 2.34 ± 1.68 48 1.50 ± 1.20 0.002
Iron serum (mcg/dL) 95 136.65 ± 133.77 31 82.77 ± 40.17 0.029
Lactate dehydrogenase (U/L) 103 977.19 ± 524.50 48 602.92 ± 339.59 <0.001
Lipid metabolism
Total Cholesterol (mg/dL) 103 116.49 ± 25.17 48 131.06 ± 25.73 0.001
LDL Cholesterol (mg/dL) 103 65.78 ± 21.47 48 63.19 ± 23.81 0.506
VLDL Cholesterol (mg/dL) 103 21.62 ± 10.31 48 17.90 ± 6.38 0.023
Triglycerides (mg/dL) 102 107.74 ± 51.64 48 90.02 ± 31.86 0.030
Hepatic
Alanine aminotransferase (U/L) 103 29.90 ± 22.10 48 24.58 ± 19.56 0.156
Total protein (g/dL) 103 7.40 ± .89 48 7.46 ± .82 0.684
Albumin (g/dL) 103 4.01 ± .75 48 4.23 ± .59 0.054
Globulin (g/dL) 103 3.36 ± .85 48 3.23 ± .72 0.333
Albumin/Globulin ratio 103 1.34 ± .55 48 1.38 ± .53 0.709
Renal
Urea nitrogen (mg/dL) 102 17.25 ± 6.70 47 18.77 ± 5.73 0.181
Creatinine (mg/dL) 103 0.49 ±0.50 47 0.57 ± 0.50 0.315
Inflammation
C-reactive protein (mg/L) 101 7.79 ± 14.02 46 5.39 ± 5.18 0.133
Alpha 1 antitrypsin (mg/dL) 102 163.13 ± 44.06 48 128.92 ± 42.13 <0.001
Ferritin (ng/mL) 103 300.76 ± 399.59 46 323.46 ± 348.87 0.740
Antistreptolysin O (UI/mL) 101 198.62 ± 288.98 46 183 ± 282.56 0.759
* unpaired t-test ** 80 HBSS and 23 HBSC ***23 HBSS and 25 HBSC
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concentration, may function as a prognostic marker of
intravascular hemolysis and endothelial dysfunction
given its anti-inflammatory, anti-oxidative, anti-aggrega-
tion, anti-coagulant and pro-fibrinolytic activities
[25,26].
Sickle cell disease patients with higher HDL-C levels
presented a low risk of hemolysis and endothelial dys-
function, including lower reticulocyte and erythroblast
counts as well as a lower HbS concentration and it may
be related to the high consumption of cholesterol due
to acceleration of blood marrow cell production during
hemolysis crisis. Sickle cell disease patients with higher
HDL-C levels had lower leukocyte, monocyte and plate-
let counts as well as a lower concentration of hepatic
and hemolytic markers and significantly lower VLDL-C,
triglycerides and A1AT concentrations; this may reflect
the action of the anti-inflammatory and anti-oxidative
properties of this biomarker [25,26]. The high-density
lipoprotein cholesterol removes excess cholesterol from
peripheral tissues and transports it to the liver for excre-
tion via bile by reverse cholesterol transport. The high-
density lipoprotein is made up of several particles with
different composition and function [24,27,28].
Further confirmation of these associations came from
comparing HDL-C concentrations and patients’ clinical
records, which revealed a higher occurrence of pneu-
monia and cardiac abnormalities among those with
lower HDL-C levels. The results related to pneumonia
risk can be explained by the production of auto-anti-
bodies specific to oxidized phospholipids; these auto-
antibodies have been shown to inhibit macrophage
uptake of oxidized LDL and to provide protection
against virulent pneumococcal infection [29]. Low
levels of HDL-C are an important cardiovascular risk
factor, and HDL-C and apoA-I have been shown to
decrease lesions and improve vascular reactivity in ani-
mal models of atherosclerosis and in humans; these
changes may be due to the reduction of oxidized lipids
and the enhancement of reverse cholesterol transport
[30]. The presence of pulmonary hypertension was
shown to be associated with several laboratory test
alterations [31]. Recent study has also demonstrated
the important role of the apolipoprotein pathway and
its association with endothelial dysfunction in SCD
patients with pulmonary hypertension [31].
Patients with lower HDL-C levels were also likely to
have had more blood transfusions; this can be linked
with a more severe clinical course of disease, once that
it is a therapeutic strategy used to prevent several clini-
cal symptoms, such as stroke [1].
It is well known that gallstones in patients with hemo-
lytic anemia are said to be calcium bilirubinate stones.
In view our results of correlation of cholesterol and tri-
glycerides with hemolysis, we propose that the stones in
SCD patients could be related directly to hemolysis and
bilirubin generation, and indirectly to cholesterol and
lipids and it could be a novel observation and needs to
be confirmed by further studies. The association of
acute-phase proteins and cholelithiasis may be explained
by the response to stress due to traumatic injury or
infection-related mechanisms including hypermetabo-
lism and protein catabolism associated with a cytokine-
driven inflammatory response.
Conclusions
In conclusion, we hypothesize that some SCD patients
can have a specific dyslipidemic subphenotype charac-
terized by low HDL-C with hypertriglyceridemia and
high VLDL-C in association with other biomarkers,
including those related to inflammation. This represents
an important step toward a more reliable clinical
Figure 1 Box-plots of cholelithiasis and biochemical markers
among sickle cell disease steady-state children. Number 0
represents absence and 1 presence of cholelithiasis (COLELIT)
analyzed accord to different serum concentrations of triglycerides
(TRIG) (P = 0.047), very-low density lipoprotein cholesterol (VLDLC)
(P = 0.044), low-density lipoprotein cholesterol (LDLC) (P = 0.033),
total cholesterol (P = 0.007), high-density lipoprotein cholesterol
(HDLC) (P = 0.349), alpha 1-antitrypsin (A1AT) (P = 0.040) and ferritin
(FERRIT) (P = 0.008). The p values were estimated by the Kruskal-
Wallis test.
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prognosis. Additional studies are warranted to test this
hypothesis and the probably mechanisms involved in
this complex network of markers and their role in SCD
pathogenesis.
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